BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28514751)

  • 1. Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach.
    Park J; Lee E; Park KJ; Park HD; Kim JW; Woo HI; Lee KH; Lee KT; Lee JK; Park JO; Park YS; Heo JS; Choi SH; Choi DW; Jang KT; Lee SY
    Oncotarget; 2017 Jun; 8(26):42761-42771. PubMed ID: 28514751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Validation of Biomarkers That Distinguish Mucinous and Nonmucinous Pancreatic Cysts.
    Park J; Yun HS; Lee KH; Lee KT; Lee JK; Lee SY
    Cancer Res; 2015 Aug; 75(16):3227-35. PubMed ID: 26122842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue.
    Zhou Q; Andersson R; Hu D; Bauden M; Kristl T; Sasor A; Pawłowski K; Pla I; Hilmersson KS; Zhou M; Lu F; Marko-Varga G; Ansari D
    EBioMedicine; 2019 May; 43():282-294. PubMed ID: 30982764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method.
    Nie S; Yin H; Tan Z; Anderson MA; Ruffin MT; Simeone DM; Lubman DM
    J Proteome Res; 2014 Dec; 13(12):6058-66. PubMed ID: 25393578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer.
    Wu X; Zhang ZX; Chen XY; Xu YL; Yin N; Yang J; Zhu DM; Li DC; Zhou J
    Proteomics Clin Appl; 2019 Sep; 13(5):e1800195. PubMed ID: 31025496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline.
    Liu X; Zheng W; Wang W; Shen H; Liu L; Lou W; Wang X; Yang P
    Br J Cancer; 2017 Dec; 117(12):1846-1854. PubMed ID: 29123261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.
    Pan S; Chen R; Crispin DA; May D; Stevens T; McIntosh MW; Bronner MP; Ziogas A; Anton-Culver H; Brentnall TA
    J Proteome Res; 2011 May; 10(5):2359-76. PubMed ID: 21443201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
    Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
    J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry.
    Yu KH; Rustgi AK; Blair IA
    J Proteome Res; 2005; 4(5):1742-51. PubMed ID: 16212428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis.
    Saraswat M; Joenväärä S; Seppänen H; Mustonen H; Haglund C; Renkonen R
    Cancer Med; 2017 Jul; 6(7):1738-1751. PubMed ID: 28573829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytically validated protein biomarkers of chronic pancreatitis and pancreatic cancer for potential clinical diagnosis with mass spectrometry.
    Chou CY; Chang CT; Chen CJ
    Rapid Commun Mass Spectrom; 2020 Apr; 34 Suppl 1():e8580. PubMed ID: 31502717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer.
    Chen R; Brentnall TA; Pan S; Cooke K; Moyes KW; Lane Z; Crispin DA; Goodlett DR; Aebersold R; Bronner MP
    Mol Cell Proteomics; 2007 Aug; 6(8):1331-42. PubMed ID: 17496331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
    Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
    Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
    Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
    Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
    Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
    Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
    Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of putative pancreatic cancer biomarkers using subcellular proteomics.
    McKinney KQ; Lee YY; Choi HS; Groseclose G; Iannitti DA; Martinie JB; Russo MW; Lundgren DH; Han DK; Bonkovsky HL; Hwang SI
    J Proteomics; 2011 Jan; 74(1):79-88. PubMed ID: 20807598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis.
    Lukic N; Visentin R; Delhaye M; Frossard JL; Lescuyer P; Dumonceau JM; Farina A
    Biochim Biophys Acta; 2014 May; 1844(5):1026-33. PubMed ID: 23872482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics.
    Hirata Y; Kobayashi T; Nishiumi S; Yamanaka K; Nakagawa T; Fujigaki S; Iemoto T; Kobayashi M; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Yamada T; Honda K; Azuma T; Yoshida M
    Clin Chim Acta; 2017 May; 468():98-104. PubMed ID: 28215548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms.
    Rebours V; Le Faouder J; Laouirem S; Mebarki M; Albuquerque M; Camadro JM; Léger T; Ruszniewski P; Lévy P; Paradis V; Bedossa P; Couvelard A
    Pancreatology; 2014; 14(2):117-24. PubMed ID: 24650966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.